Mineralys Therapeutics Inc (NASDAQ:MLYS) is developing precision therapies for cardiovascular and kidney diseases. Recent insider transactions, including shares sold at $12.7 each, show a balanced activity pattern. Investors should assess valuation metrics and insider trends when considering investment decisions.